15 Best Biotech Penny Stocks to Invest in Right Now

Page 12 of 13

2. I-Mab (NASDAQ:IMAB)

Year-to-Date Return: 330.68% 

I-Mab (NASDAQ:IMAB) is a U.S.-based biotechnology company focused on precision immuno-oncology, developing differentiated therapies for cancer. Its lead candidate, givastomig, is a bispecific antibody targeting Claudin 18.2 and 4-1BB, designed to selectively activate T cells within the tumor microenvironment, aiming to maximize anti-tumor effects while reducing common toxicities of other 4-1BB agents.

In September 2025, the corporation participated in major investor conferences, including the Cantor Global Healthcare Conference and the H.C. Wainwright 27th Annual Global Investment Conference, where it showcased its strategic vision and pipeline progress.

Key clinical progress includes positive Phase 1b dose escalation results for givastomig in combination with immunochemotherapy for first-line metastatic gastric cancer, presented at the ESMO GI 2025 conference. The data revealed an impressive 83% objective response rate at doses selected for expansion. Enrollment in the Phase 1b expansion cohorts was completed ahead of schedule, with topline results expected in the first quarter of 2026, highlighting strong tumor-binding and anti-tumor activity.

Financially, I-Mab (NASDAQ:IMAB) bolstered its resources with an August 2025 underwritten offering raising approximately $61.2 million, bringing its pro-forma cash balance to $226.8 million as of June 30, 2025. This robust capital position is expected to fund operations through late 2028, supporting ongoing clinical development and further pipeline advancement.

Page 12 of 13